NASDAQ · ADVB

Advanced Biomed Inc.

$14.36 -$4.62 (-24.34%) 1D After hours

Key Metrics

$31.36M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$2.94M
Beta · 1Y -0.68
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    The stock moved +73.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 22
  • Jul 20
    The stock moved +76.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 20
  • Jul 17
    A material event was filed (Form 8-K).

    8-K - Advanced Biomed Inc. (0001941029) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 9
    From its May 7 high, the share price fell 48%.

    Peak close $7.20 on May 7; trough close $3.71 on Jun 9. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -48%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$31.36M
Enterprise value
Shares outstanding1.7M
52-wk range$0.31 – $24.23
Avg volume · 20D845.5K
Net cash
Book value / share$5.57
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Advanced Biomed Inc.
IPO dateMar 6, 2025
Employees31

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio7.38
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$9.10M

Cash Flow · TTM

Operating CF −$2.91M
Capex −$36.09K
Free cash flow −$2.94M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings